Showing results (1-10 of 947) with videos related to

Sort By:
Pageof 95
British Journal of Cancer|August 4, 2023
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategiesAustin Wesevich, Daniel A Goldstein, Koosha Paydary, et al.
British Journal of Clinical Pharmacology|May 20, 2020
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitorsCody J Peer, Daniel A Goldstein, Jennifer C Goodell, et al.
Journal of Clinical Pharmacology|October 14, 2021
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose DeescalationCody J Peer, Brian L Heiss, Daniel A Goldstein, et al.
Journal of Clinical Pharmacology|January 10, 2023
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response SimulationCody J Peer, Keith T Schmidt, Oluwatobi Arisa, et al.
Cancer Biology & Therapy|January 29, 2011
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agentsCody J Peer, Tristan M Sissung, William D Figg
Cancer Biology & Therapy|August 7, 2013
Uncovering the genetic landscape driving castration-resistant prostate cancerTimothy J Martin, Cody J Peer, William D Figg
Cancer Biology & Therapy|May 18, 2018
Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnosticsO Morgan Hall, Cody J Peer, William D Figg
Cancer Biology & Therapy|October 11, 2021
Ibrutinib's off-target mechanism: cause for dose optimizationSara M Zimmerman, Cody J Peer, William D Figg
Pageof 95